Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Oncology Right
  3. Cyramza (ramucirumab) injection Right
  4. What is Cyramza® (ramucirumab) used for?
Search Cyramza (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Cyramza ® (ramucirumab) injection

10 mg/mL solution

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

What is Cyramza® (ramucirumab) used for?

Cyramza (ramucirumab) is indicated for the treatment of patients with gastric/gastroesophageal junction adenocarcinoma, metastatic non-small cell lung cancer, metastatic colorectal cancer, and hepatocellular carcinoma.

US_cFAQ_RAM002_INDICATION
US_cFAQ_RAM002_INDICATION
en-US

Detailed Information

Ramucirumab is a human vascular endothelial growth factor receptor 2 antagonist indicated

  • as a single agent or in combination with paclitaxel, for treatment of advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy
  • in combination with erlotinib, for first-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations
  • in combination with docetaxel, for treatment of metastatic NSCLC with disease progression on or after platinum-based chemotherapy
    • patients with EGFR or anaplastic lymphoma kinase genomic tumor aberrations should have disease progression on Food and Drug Administration–approved therapy for these aberrations prior to receiving ramucirumab
  • in combination with irinotecan, folinic acid, and 5-fluorouracil, for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine, and
  • as a single agent, for the treatment of hepatocellular carcinoma in patients who have an alpha-fetoprotein ≥400 ng/mL and have been treated with sorafenib.1

Enclosed Prescribing Information

CYRAMZA® (ramucirumab) injection, for intravenous use, Lilly

Reference

1Cyramza [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.

Date of Last Review: February 10, 2023

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Lilly